Prognia
Drug Database
🇪🇺EU · EMAAuthorisedATC: J05AR17

Descovy(emtricitabine;tenofovir alafenamide)

HIV Infections

Marketing Authorisation Holder: Gilead Sciences Ireland UC

EMA Authorisation: 21/04/2016

INN: emtricitabine;tenofovir alafenamide

Indication

Descovy is indicated in combination with other antiretroviral agents for the treatment of adults and adolescents (aged 12 years and older with body weight at least 35 kg) infected with human immunodeficiency virus type 1 (HIV-1).

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Descovy — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.